Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition.

Mitra R, Chen X, Greenawalt EJ, Maulik U, Jiang W, Zhao Z, Eischen CM.

Nat Commun. 2017 Nov 17;8(1):1604. doi: 10.1038/s41467-017-01781-0.

2.

Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW.

Adams CM, Mitra R, Gong JZ, Eischen CM.

Clin Cancer Res. 2017 Nov 15;23(22):7119-7129. doi: 10.1158/1078-0432.CCR-17-1144. Epub 2017 Aug 29.

PMID:
28855351
3.

Mdm2 Is Required for Survival and Growth of p53-Deficient Cancer Cells.

Feeley KP, Adams CM, Mitra R, Eischen CM.

Cancer Res. 2017 Jul 15;77(14):3823-3833. doi: 10.1158/0008-5472.CAN-17-0809. Epub 2017 Jun 2.

PMID:
28576884
4.

Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.

Moyo TK, Wilson CS, Moore DJ, Eischen CM.

Oncogene. 2017 Aug 10;36(32):4653-4661. doi: 10.1038/onc.2017.95. Epub 2017 Apr 3.

5.

BCL-W has a fundamental role in B cell survival and lymphomagenesis.

Adams CM, Kim AS, Mitra R, Choi JK, Gong JZ, Eischen CM.

J Clin Invest. 2017 Feb 1;127(2):635-650. doi: 10.1172/JCI89486. Epub 2017 Jan 17.

6.

Role of Mdm2 and Mdmx in DNA repair.

Eischen CM.

J Mol Cell Biol. 2017 Feb 1;9(1):69-73. doi: 10.1093/jmcb/mjw052. Review.

7.

Haploinsufficiency of the Myc regulator Mtbp extends survival and delays tumor development in aging mice.

Grieb BC, Boyd K, Mitra R, Eischen CM.

Aging (Albany NY). 2016 Oct 30;8(10):2590-2602. doi: 10.18632/aging.101092.

8.

Defective replication stress response inhibits lymphomagenesis and impairs lymphocyte reconstitution.

Puccetti MV, Fischer MA, Arrate MP, Boyd KL, Duszynski RJ, Bétous R, Cortez D, Eischen CM.

Oncogene. 2017 May 4;36(18):2553-2564. doi: 10.1038/onc.2016.408. Epub 2016 Oct 31.

9.

The Potential Roles of Long Noncoding RNAs (lncRNA) in Glioblastoma Development.

Liu S, Mitra R, Zhao MM, Fan W, Eischen CM, Yin F, Zhao Z.

Mol Cancer Ther. 2016 Dec;15(12):2977-2986. doi: 10.1158/1535-7163.MCT-16-0320. Epub 2016 Oct 26.

10.

Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer.

Oran AR, Adams CM, Zhang XY, Gennaro VJ, Pfeiffer HK, Mellert HS, Seidel HE, Mascioli K, Kaplan J, Gaballa MR, Shen C, Rigoutsos I, King MP, Cotney JL, Arnold JJ, Sharma SD, Martinez-Outschoorn UE, Vakoc CR, Chodosh LA, Thompson JE, Bradner JE, Cameron CE, Shadel GS, Eischen CM, McMahon SB.

Oncotarget. 2016 Nov 8;7(45):72395-72414. doi: 10.18632/oncotarget.11718.

11.

TOX expression and role in CTCL.

McGirt LY, Degesys CA, Johnson VE, Zic JA, Zwerner JP, Eischen CM.

J Eur Acad Dermatol Venereol. 2016 Sep;30(9):1497-502. doi: 10.1111/jdv.13651. Epub 2016 Jun 26.

12.

Genome Stability Requires p53.

Eischen CM.

Cold Spring Harb Perspect Med. 2016 Jun 1;6(6). pii: a026096. doi: 10.1101/cshperspect.a026096. Review.

PMID:
27252396
13.

Molecular underpinnings of HDAC inhibition revealed.

Adams CM, Eischen CM.

Cell Cycle. 2016 Aug 2;15(15):1943-4. doi: 10.1080/15384101.2016.1184513. Epub 2016 May 6. No abstract available.

14.

miR-31 and miR-17-5p levels change during transformation of follicular lymphoma.

Thompson MA, Edmonds MD, Liang S, McClintock-Treep S, Wang X, Li S, Eischen CM.

Hum Pathol. 2016 Apr;50:118-26. doi: 10.1016/j.humpath.2015.11.011. Epub 2015 Nov 30.

15.

Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma.

Adams CM, Eischen CM.

Cell Death Differ. 2016 Aug;23(8):1312-21. doi: 10.1038/cdd.2016.9. Epub 2016 Feb 26.

16.

Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies.

Adams CM, Hiebert SW, Eischen CM.

Cancer Res. 2016 Feb 1;76(3):736-48. doi: 10.1158/0008-5472.CAN-15-1751. Epub 2015 Dec 16. Erratum in: Cancer Res. 2017 Dec 1;77(23 ):6789.

17.

MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer.

Edmonds MD, Boyd KL, Moyo T, Mitra R, Duszynski R, Arrate MP, Chen X, Zhao Z, Blackwell TS, Andl T, Eischen CM.

J Clin Invest. 2016 Jan;126(1):349-64. doi: 10.1172/JCI82720. Epub 2015 Dec 14.

18.

SMARCAL1 maintains telomere integrity during DNA replication.

Poole LA, Zhao R, Glick GG, Lovejoy CA, Eischen CM, Cortez D.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14864-9. doi: 10.1073/pnas.1510750112. Epub 2015 Nov 17.

19.

Interaction of MYC with host cell factor-1 is mediated by the evolutionarily conserved Myc box IV motif.

Thomas LR, Foshage AM, Weissmiller AM, Popay TM, Grieb BC, Qualls SJ, Ng V, Carboneau B, Lorey S, Eischen CM, Tansey WP.

Oncogene. 2016 Jul 7;35(27):3613-8. doi: 10.1038/onc.2015.416. Epub 2015 Nov 2.

20.

Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.

Tonsing-Carter E, Bailey BJ, Saadatzadeh MR, Ding J, Wang H, Sinn AL, Peterman KM, Spragins TK, Silver JM, Sprouse AA, Georgiadis TM, Gunter TZ, Long EC, Minto RE, Marchal CC, Batuello CN, Safa AR, Hanenberg H, Territo PR, Sandusky GE, Mayo LD, Eischen CM, Shannon HE, Pollok KE.

Mol Cancer Ther. 2015 Dec;14(12):2850-63. doi: 10.1158/1535-7163.MCT-15-0237. Epub 2015 Oct 22.

21.

Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.

McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, Zwerner JP, Hucks D, Dave U, Zhao Z, Eischen CM.

Blood. 2015 Jul 23;126(4):508-19. doi: 10.1182/blood-2014-11-611194. Epub 2015 Jun 16.

22.

Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.

Carrillo AM, Hicks M, Khabele D, Eischen CM.

Mol Cancer Res. 2015 Aug;13(8):1197-205. doi: 10.1158/1541-7786.MCR-15-0089. Epub 2015 May 11.

23.

Concordant dysregulation of miR-5p and miR-3p arms of the same precursor microRNA may be a mechanism in inducing cell proliferation and tumorigenesis: a lung cancer study.

Mitra R, Lin CC, Eischen CM, Bandyopadhyay S, Zhao Z.

RNA. 2015 Jun;21(6):1055-65. doi: 10.1261/rna.048132.114. Epub 2015 Apr 7.

24.

Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC.

Thomas LR, Wang Q, Grieb BC, Phan J, Foshage AM, Sun Q, Olejniczak ET, Clark T, Dey S, Lorey S, Alicie B, Howard GC, Cawthon B, Ess KC, Eischen CM, Zhao Z, Fesik SW, Tansey WP.

Mol Cell. 2015 May 7;58(3):440-52. doi: 10.1016/j.molcel.2015.02.028. Epub 2015 Mar 26.

25.

Cell survival is dicey without Dicer.

Adams CM, Eischen CM.

Mol Cell Oncol. 2014 Jun;1(2). pii: e961825.

26.

Differences in miRNA expression in early stage lung adenocarcinomas that did and did not relapse.

Edmonds MD, Eischen CM.

PLoS One. 2014 Jul 16;9(7):e101802. doi: 10.1371/journal.pone.0101802. eCollection 2014.

27.

Reproducible combinatorial regulatory networks elucidate novel oncogenic microRNAs in non-small cell lung cancer.

Mitra R, Edmonds MD, Sun J, Zhao M, Yu H, Eischen CM, Zhao Z.

RNA. 2014 Sep;20(9):1356-68. doi: 10.1261/rna.042754.113. Epub 2014 Jul 14.

28.

Early changes in miRNA expression are predictive of response to extracorporeal photopheresis in cutaneous T-cell lymphoma.

McGirt LY, Baerenwald DA, Vonderheid EC, Eischen CM.

J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2269-71. doi: 10.1111/jdv.12571. Epub 2014 Jun 9. No abstract available.

29.

MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival.

Grieb BC, Chen X, Eischen CM.

Mol Cancer Res. 2014 Sep;12(9):1216-24. doi: 10.1158/1541-7786.MCR-14-0069. Epub 2014 May 27.

30.

Inactivation of p53 is insufficient to allow B cells and B-cell lymphomas to survive without Dicer.

Adams CM, Eischen CM.

Cancer Res. 2014 Jul 15;74(14):3923-34. doi: 10.1158/0008-5472.CAN-13-1866. Epub 2014 May 19.

31.

Oncogenic protein MTBP interacts with MYC to promote tumorigenesis.

Grieb BC, Gramling MW, Arrate MP, Chen X, Beauparlant SL, Haines DS, Xiao H, Eischen CM.

Cancer Res. 2014 Jul 1;74(13):3591-602. doi: 10.1158/0008-5472.CAN-13-2149. Epub 2014 May 1.

32.

Mdmx promotes genomic instability independent of p53 and Mdm2.

Carrillo AM, Bouska A, Arrate MP, Eischen CM.

Oncogene. 2015 Feb 12;34(7):846-56. doi: 10.1038/onc.2014.27. Epub 2014 Mar 10.

33.

The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.

Eischen CM, Lozano G.

Hum Mutat. 2014 Jun;35(6):728-37. doi: 10.1002/humu.22524. Epub 2014 Mar 6. Review.

34.

miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.

McGirt LY, Adams CM, Baerenwald DA, Zwerner JP, Zic JA, Eischen CM.

J Invest Dermatol. 2014 Apr;134(4):1101-1107. doi: 10.1038/jid.2013.461. Epub 2013 Nov 7.

35.

RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts.

Zhang X, Hagen J, Muniz VP, Smith T, Coombs GS, Eischen CM, Mackie DI, Roman DL, Van Rheeden R, Darbro B, Tompkins VS, Quelle DE.

PLoS One. 2013 Nov 25;8(11):e80228. doi: 10.1371/journal.pone.0080228. eCollection 2013.

36.

Genetic markers associated with progression in early mycosis fungoides.

Johnson VE, Vonderheid EC, Hess AD, Eischen CM, McGirt LY.

J Eur Acad Dermatol Venereol. 2014 Nov;28(11):1431-5. doi: 10.1111/jdv.12299. Epub 2013 Oct 31.

37.

Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.

Wells CE, Bhaskara S, Stengel KR, Zhao Y, Sirbu B, Chagot B, Cortez D, Khabele D, Chazin WJ, Cooper A, Jacques V, Rusche J, Eischen CM, McGirt LY, Hiebert SW.

PLoS One. 2013 Jul 22;8(7):e68915. doi: 10.1371/journal.pone.0068915. Print 2013.

38.

Protecting the genome from mdm2 and mdmx.

Melo AN, Eischen CM.

Genes Cancer. 2012 Mar;3(3-4):283-90. doi: 10.1177/1947601912454139.

39.

Decreased Mdm2 expression inhibits tumor development and extends survival independent of Arf and dependent on p53.

Eischen CM, Boyd K.

PLoS One. 2012;7(9):e46148. doi: 10.1371/journal.pone.0046148. Epub 2012 Sep 28.

40.

Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis.

Anderson PD, McKissic SA, Logan M, Roh M, Franco OE, Wang J, Doubinskaia I, van der Meer R, Hayward SW, Eischen CM, Eltoum IE, Abdulkadir SA.

J Clin Invest. 2012 May;122(5):1907-19. doi: 10.1172/JCI58540. Epub 2012 Apr 9.

41.

Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis.

Gramling MW, Eischen CM.

Cell Death Differ. 2012 Jul;19(7):1220-7. doi: 10.1038/cdd.2012.1. Epub 2012 Feb 3.

42.

Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family.

Cho SH, Ahn AK, Bhargava P, Lee CH, Eischen CM, McGuinness O, Boothby M.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15972-7. doi: 10.1073/pnas.1017082108. Epub 2011 Sep 12.

43.

Aging mice have increased chromosome instability that is exacerbated by elevated Mdm2 expression.

Lushnikova T, Bouska A, Odvody J, Dupont WD, Eischen CM.

Oncogene. 2011 Nov 17;30(46):4622-31. doi: 10.1038/onc.2011.172. Epub 2011 May 23.

44.

Decreased Mdm2 levels after DNA damage: antibody masking or protein degradation?

Eischen CM.

Cell Cycle. 2011 May 1;10(9):1347. Epub 2011 May 1. No abstract available.

PMID:
21460638
45.

MicroRNA biogenesis is required for Myc-induced B-cell lymphoma development and survival.

Arrate MP, Vincent T, Odvody J, Kar R, Jones SN, Eischen CM.

Cancer Res. 2010 Jul 15;70(14):6083-92. doi: 10.1158/0008-5472.CAN-09-4736. Epub 2010 Jun 29.

46.

A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis.

Odvody J, Vincent T, Arrate MP, Grieb B, Wang S, Garriga J, Lozano G, Iwakuma T, Haines DS, Eischen CM.

Oncogene. 2010 Jun 3;29(22):3287-96. doi: 10.1038/onc.2010.82. Epub 2010 Mar 22.

47.

Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis.

Sluss HK, Gannon H, Coles AH, Shen Q, Eischen CM, Jones SN.

Mol Cancer Res. 2010 Feb;8(2):216-22. doi: 10.1158/1541-7786.MCR-09-0324. Epub 2010 Feb 9.

48.

p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis.

Post SM, Quintás-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G.

Oncogene. 2010 Mar 4;29(9):1260-9. doi: 10.1038/onc.2009.423. Epub 2009 Nov 23.

49.

Murine double minute 2: p53-independent roads lead to genome instability or death.

Bouska A, Eischen CM.

Trends Biochem Sci. 2009 Jun;34(6):279-86. doi: 10.1016/j.tibs.2009.02.006. Epub 2009 May 15. Review.

PMID:
19447627
50.

p53 and MDM2: antagonists or partners in crime?

Eischen CM, Lozano G.

Cancer Cell. 2009 Mar 3;15(3):161-2. doi: 10.1016/j.ccr.2009.02.004. Review.

Supplemental Content

Loading ...
Support Center